Reducing gut microbiome-driven adipose tissue inflammation alleviates metabolic syndrome

被引:12
|
作者
Newman, N. K. [1 ]
Zhang, Y. [2 ,3 ]
Padiadpu, J. [1 ]
Miranda, C. L. [4 ]
Magana, A. A. [5 ]
Wong, C. P. [2 ]
Hioki, K. A. [1 ,6 ]
Pederson, J. W. [7 ]
Li, Z. [7 ]
Gurung, M. [7 ,8 ]
Bruce, A. M. [1 ]
Brown, K. [1 ,9 ]
Bobe, G. [10 ]
Sharpton, T. J. [11 ]
Shulzhenko, N. [7 ]
Maier, C. S. [5 ]
Stevens, J. F. [4 ]
Gombart, A. F. [12 ]
Morgun, A. [1 ]
机构
[1] Oregon State Univ, Coll Pharm, Dept Pharmaceut Sci, Corvallis, OR 97331 USA
[2] Oregon State Univ, Linus Pauling Inst, Sch Biol & Populat Hlth Sci, Nutr Program, Corvallis, OR USA
[3] Oregon Hlth & Sci Univ, Portland, OR USA
[4] Oregon State Univ, Linus Pauling Inst, Dept Pharmaceut Sci, Corvallis, OR USA
[5] Oregon State Univ, Linus Pauling Inst, Dept Chem, Corvallis, OR USA
[6] UMass, Amherst, MA USA
[7] Oregon State Univ, Carlson Coll Vet Med, Dept Biomed Sci, Corvallis, OR 97331 USA
[8] USDA, Children Nutr Ctr, Little Rock, AR USA
[9] Oregon State Univ, Chem Biol & Environm Engn, Corvallis, OR USA
[10] Oregon State Univ, Linus Pauling Inst, Dept Anim Sci, Corvallis, OR 97331 USA
[11] Oregon State Univ, Dept Microbiol, Dept Stat, Corvallis, OR USA
[12] Linus Pauling Inst, Dept Biochem & Biophys, Corvallis, OR 97331 USA
关键词
HUMULUS-LUPULUS L; LIPID-METABOLISM; XANTHOHUMOL; GLUCOSE; MACROPHAGES; MECHANISMS; OBESITY; HEALTH; HOST; HOP;
D O I
10.1186/s40168-023-01637-4
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
BackgroundThe gut microbiota contributes to macrophage-mediated inflammation in adipose tissue with consumption of an obesogenic diet, thus driving the development of metabolic syndrome. There is a need to identify and develop interventions that abrogate this condition. The hops-derived prenylated flavonoid xanthohumol (XN) and its semi-synthetic derivative tetrahydroxanthohumol (TXN) attenuate high-fat diet-induced obesity, hepatosteatosis, and metabolic syndrome in C57Bl/6J mice. This coincides with a decrease in pro-inflammatory gene expression in the gut and adipose tissue, together with alterations in the gut microbiota and bile acid composition.ResultsIn this study, we integrated and interrogated multi-omics data from different organs with fecal 16S rRNA sequences and systemic metabolic phenotypic data using a Transkingdom Network Analysis. By incorporating cell type information from single-cell RNA-seq data, we discovered TXN attenuates macrophage inflammatory processes in adipose tissue. TXN treatment also reduced levels of inflammation-inducing microbes, such as Oscillibacter valericigenes, that lead to adverse metabolic phenotypes. Furthermore, in vitro validation in macrophage cell lines and in vivo mouse supplementation showed addition of O. valericigenes supernatant induced the expression of metabolic macrophage signature genes that are downregulated by TXN in vivo.ConclusionsOur findings establish an important mechanism by which TXN mitigates adverse phenotypic outcomes of diet-induced obesity and metabolic syndrome. TXN primarily reduces the abundance of pro-inflammatory gut microbes that can otherwise promote macrophage-associated inflammation in white adipose tissue.7MrSGPEkxmDTc41cVX6rPoVideo AbstractConclusionsOur findings establish an important mechanism by which TXN mitigates adverse phenotypic outcomes of diet-induced obesity and metabolic syndrome. TXN primarily reduces the abundance of pro-inflammatory gut microbes that can otherwise promote macrophage-associated inflammation in white adipose tissue.7MrSGPEkxmDTc41cVX6rPoVideo Abstract
引用
收藏
页数:18
相关论文
共 50 条
  • [21] Adipose tissue inflammation and metabolic syndrome. The proactive role of probiotics
    Sebastian Torres
    Emanuel Fabersani
    Antonela Marquez
    Paola Gauffin-Cano
    European Journal of Nutrition, 2019, 58 : 27 - 43
  • [22] A gut-oral microbiome-driven axis controls oropharyngeal candidiasis through retinoic acid
    Aggor, Felix E. Y.
    Bertolini, Martinna
    Zhou, Chunsheng
    Taylor, Tiffany C.
    Abbott, Darryl A.
    Musgrove, Javonn
    Bruno, Vincent M.
    Hand, Timothy W.
    Gaffen, Sarah L.
    JCI INSIGHT, 2022, 7 (18)
  • [23] Adipose tissue and the metabolic syndrome
    Frayn, KN
    CLINICA CHIMICA ACTA, 2005, 355 : S17 - S17
  • [24] Gut microbiome supplementation as therapy for metabolic syndrome
    Antony, Mc Anto
    Chowdhury, Aniqa
    Edem, Dinesh
    Raj, Rishi
    Nain, Priyanshu
    Joglekar, Mansi
    Verma, Vipin
    Kant, Ravi
    WORLD JOURNAL OF DIABETES, 2023, 14 (10) : 1502 - 1513
  • [25] Gut Microbiome in Obesity, Metabolic Syndrome, and Diabetes
    Chen, Xinpu
    Devaraj, Sridevi
    CURRENT DIABETES REPORTS, 2018, 18 (12)
  • [26] Gut Microbiome in Obesity, Metabolic Syndrome, and Diabetes
    Xinpu Chen
    Sridevi Devaraj
    Current Diabetes Reports, 2018, 18
  • [27] Metabolic syndrome and synbiotic targeting of the gut microbiome
    Nunez-Sanchez, Maria A.
    Herisson, Florence M.
    Cluzel, Gaston L.
    Caplice, Noel M.
    CURRENT OPINION IN FOOD SCIENCE, 2021, 41 : 60 - 69
  • [28] Talabostat Alleviates Obesity and Associated Metabolic Dysfunction via Suppression of Macrophage-Driven Adipose Inflammation
    Wu, Yunyun
    Shi, Tiancong
    Wang, Jiqiu
    He, Rui
    OBESITY, 2021, 29 (02) : 327 - 336
  • [29] Effects of colchicine on lipolysis and adipose tissue inflammation in adults with obesity and metabolic syndrome
    Levine, Jordan A.
    Sarrafan-Chaharsoughi, Zahra
    Patel, Tushar P.
    Brady, Sheila M.
    Chivukula, K. Karthik
    Miller, Emily
    Han, Jung Min
    Periwal, Vipul
    Wolska, Anna
    Remaley, Alan T.
    Dagur, Pradeep K.
    Biancotto, Angelique
    Babyak, Ashley
    Fantoni, Giovanna
    Yanovski, Jack A.
    Demidowich, Andrew P.
    OBESITY, 2022, 30 (02) : 358 - 368
  • [30] VISCERAL ADIPOSE TISSUE, INFLAMMATION AND FIBROSIS IN PATIENTS WITH ATRIAL FIBRILLATION AND METABOLIC SYNDROME
    Ionin, V.
    Zaslavskaya, E.
    Ma, Y.
    Morozov, A.
    Polyakova, E.
    Nifontov, S.
    Malikov, K.
    Listopad, O.
    Belyaeva, O.
    Yashin, S.
    Baranova, E.
    Shlyakhto, E.
    ATHEROSCLEROSIS, 2018, 275 : E172 - E173